糖尿病视网膜病变的药物治疗进展
Progresses in the drug treatment of diabetic retinopathy
朱琳 1许永崧 1冯晓彤 1赵冬 1柯静1
作者信息
- 1. 首都医科大学附属北京潞河医院内分泌代谢与免疫性疾病中心 糖尿病防治研究北京市重点实验室,北京 101149
- 折叠
摘要
糖尿病视网膜病变(diabetic retinopathy,DR)是糖尿病常见的微血管并发症之一,也是目前导致成人失明的主要原因.近年来DR的治疗手段不断丰富,其中药物治疗相关的临床和基础研究更是获得了很大的进展.本文总结了DR相关治疗药物的现况和进展,包括羟苯磺酸钙(calcium dobesilate,CAD)、胰激肽原酶(pancreatic kininogenase,PK)、非诺贝特(fenofibrate)、抗血管内皮生长因子(anti-vascular endothelial growth factor,anti-VEGF)药物、胰高血糖素样肽-1 受体激动剂(glucagon-like peptide-1 receptor agonist,GLP-1RA)、钠-葡萄糖共同转运蛋白2 抑制剂(sodium-dependent glucose transporter 2 inhibitors,SGLT-2i)、非奈利酮(finerenone)、抗氧化剂、天然产物及褪黑素(melatonin)等.
Abstract
Diabetic retinopathy(DR)is one of the common microvascular complications of diabetes and it is the main cause of blindness in adults.In recent years,the treatment of DR has been enriched,and the clinical and basic research related to drug therapy has made great progress.This article summarized the current agents used to treat DR,including calcium dobesilate(CAD),pancreatic kininogenase(PK),fenofibrate,anti-vascular endothelial growth factor(anti-VEGF)drugs,glucagon-like peptide-1 receptor agonist(GLP-1RA),sodium-dependent glucose transporter 2 inhibitors(SGLT-2i),finerenone,antioxidants,natural products and melatonin.
关键词
糖尿病视网膜病变/药物治疗/研究进展Key words
diabetes retinopathy/drug treatment/research progress引用本文复制引用
基金项目
北京市科技新星计划(20220484039)
出版年
2024
NETL
NSTL
万方数据